Atacicept Reduces Hematuria and Serum Gd-IgA1, Both Associated with Long-term Renal Outcomes in IgAN: 36 Week Results from the Phase 2b ORIGIN Study (346da2)

Vera Therapeutics Inc. published this content on November 07, 2023, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 16, 2025 at 09:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io